RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Brian Wong, will present at the 41^st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:00 p.m. PT. The conference provides a platform for companies to discuss innovations in healthcare. RAPT focuses on developing oral small molecule therapies for inflammatory diseases and oncology. Their notable drug candidates include RPT193 and FLX475, targeting CCR4 receptors. A live webcast of the presentation will be available on their official website.

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 41^st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:00 p.m. Pacific Time.

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

FAQ

What is RAPT Therapeutics' focus in the biopharmaceutical industry?

RAPT Therapeutics specializes in developing oral small molecule therapies aimed at inflammatory diseases and oncology.

When will Brian Wong present at the J.P. Morgan Healthcare Conference?

Brian Wong will present on January 10, 2023, at 3:00 p.m. Pacific Time.

How can I access the RAPT Therapeutics conference presentation?

You can access the live webcast and archived recording of the presentation on the RAPT Therapeutics website.

What are RAPT Therapeutics' key drug candidates?

RAPT Therapeutics has developed two key drug candidates: RPT193 and FLX475, both targeting the CCR4 receptors.

What can we expect from RAPT Therapeutics at the conference?

Expect insights on RAPT’s developments in drug discovery and updates on their ongoing clinical trials.